CN103096891A - 利用羟氯喹或羟氯喹和抗病毒剂的组合治疗丙型肝炎病毒相关疾病 - Google Patents

利用羟氯喹或羟氯喹和抗病毒剂的组合治疗丙型肝炎病毒相关疾病 Download PDF

Info

Publication number
CN103096891A
CN103096891A CN2011800411855A CN201180041185A CN103096891A CN 103096891 A CN103096891 A CN 103096891A CN 2011800411855 A CN2011800411855 A CN 2011800411855A CN 201180041185 A CN201180041185 A CN 201180041185A CN 103096891 A CN103096891 A CN 103096891A
Authority
CN
China
Prior art keywords
hcv
antiviral agent
hydroxychloroquine
interferon
hcq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800411855A
Other languages
English (en)
Chinese (zh)
Inventor
菲利普·哈尔丰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panmed Ltd
Genoscience Pharma SAS
Original Assignee
Panmed Ltd
Genoscience Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panmed Ltd, Genoscience Pharma SAS filed Critical Panmed Ltd
Publication of CN103096891A publication Critical patent/CN103096891A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN2011800411855A 2010-06-24 2011-06-23 利用羟氯喹或羟氯喹和抗病毒剂的组合治疗丙型肝炎病毒相关疾病 Pending CN103096891A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35801410P 2010-06-24 2010-06-24
US61/358,014 2010-06-24
PCT/IB2011/052762 WO2011161644A1 (en) 2010-06-24 2011-06-23 Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent

Publications (1)

Publication Number Publication Date
CN103096891A true CN103096891A (zh) 2013-05-08

Family

ID=44630083

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800411855A Pending CN103096891A (zh) 2010-06-24 2011-06-23 利用羟氯喹或羟氯喹和抗病毒剂的组合治疗丙型肝炎病毒相关疾病

Country Status (10)

Country Link
US (2) US8987302B2 (enExample)
EP (1) EP2585065A1 (enExample)
JP (1) JP2013529627A (enExample)
CN (1) CN103096891A (enExample)
AU (1) AU2011268498A1 (enExample)
BR (1) BR112012033022A2 (enExample)
CA (1) CA2803093A1 (enExample)
IN (1) IN2012MN02896A (enExample)
MX (1) MX2013000242A (enExample)
WO (1) WO2011161644A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114796126A (zh) * 2022-04-02 2022-07-29 复旦大学附属中山医院青浦分院(上海市青浦区中心医院) 关节腔注射用硫酸羟氯喹缓释微球及其制备方法
CN115427041A (zh) * 2020-04-20 2022-12-02 格兰尼斯制药公司 包含羟氯喹和/或氯喹的口服递送系统

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011268498A1 (en) 2010-06-24 2013-01-31 Genoscience Pharma Sas Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
WO2012176149A1 (en) 2011-06-23 2012-12-27 Panmed Ltd. Treatment of hepatitis c virus
WO2014122537A2 (en) 2013-02-05 2014-08-14 Genoscience Sa Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
CN103145811B (zh) * 2013-03-15 2014-05-07 深圳翰宇药业股份有限公司 一种合成阿拉泊韦的方法
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
US20230149515A1 (en) * 2020-04-29 2023-05-18 The Regents Of The University Of Michigan Inhibition of sars-cov-2 viral entry through oral administration of lactoferrin and uses thereof
JP7477152B2 (ja) 2020-05-12 2024-05-01 国立大学法人 宮崎大学 Ｈｔｌｖ－１関連疾患の発症予防、進展抑制または治療のための剤
US20240115607A1 (en) 2021-01-26 2024-04-11 Cytocares (Shanghai) Inc. Chimeric antigen receptor (car) constructs and nk cells expressing car constructs

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2546658A (en) 1949-07-23 1951-03-27 Sterling Drug Inc 7-chloro-4-[5-(n-ethyl-n-2-hydroxyethylamino)-2-pentyl] aminoquinoline, its acid addition salts, and method of preparation
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5314894A (en) 1992-09-15 1994-05-24 Sterling Winthrop Inc. (S)-(+)-hydroxychloroquine
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5624938A (en) * 1994-07-18 1997-04-29 The Trustees Of Columbia University In The City Of New York Use of chloroquine to treat multiple sclerosis
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6849254B1 (en) 1999-04-19 2005-02-01 Schering Corporation HCV combination therapy
WO2001081359A1 (en) 2000-04-20 2001-11-01 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
ITBO20020416A1 (it) * 2002-06-28 2003-12-29 Valpharma Sa Uso della clorochina, idrossi-clorochina e derivati 4 amino-chinolinici per l'ottenimento di un farmaco per la terapia anti retrovirale atti
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
AU2004273773B2 (en) * 2003-02-21 2008-01-24 Jarrow Formulas, Inc. Methods for treatment of HIV or malaria using combinations of chloroquine and protease inhibitors
US7410979B2 (en) 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
EP1729795B1 (en) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
JP2008506648A (ja) 2004-07-14 2008-03-06 ノバルティス アクチエンゲゼルシャフト Ｃ型肝炎（ｈｃｖ）処置のためのシクロスポリンとペグ化インターフェロンの組合せ剤の使用
WO2006109196A2 (en) 2005-02-04 2006-10-19 Tripep Ab Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
EP1913016B1 (en) 2005-08-01 2013-01-16 Merck Sharp & Dohme Corp. Macrocyclic peptides as hcv ns3 protease inhibitors
WO2010101649A2 (en) * 2009-03-05 2010-09-10 Pablo Gastaminza Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection
PL2528922T3 (pl) 2010-01-27 2018-01-31 Ab Pharma Ltd Związki poliheterocykliczne jako inhibitory hcv
AU2011268498A1 (en) 2010-06-24 2013-01-31 Genoscience Pharma Sas Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
CN103328466B (zh) 2010-11-01 2016-08-03 Rfs制药公司 Hcv ns3蛋白酶抑制剂
WO2012176149A1 (en) 2011-06-23 2012-12-27 Panmed Ltd. Treatment of hepatitis c virus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOUROUMALIS E A: "Hydroxychloroquine reduces liver related mortality in hepatitis C associated (HCV) compensated cirrhosis", 《GUT》 *
ZUCKERMAN E ET AL: "Management of hepatitis C virus-related arthritis", 《BIODRUGS:CLINICAL IMMUNOTHERAPEUTICS, BIOPHARMACEUTICALS AND GENE THERAPY 2001 LNKD-PUBMED:11580301》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115427041A (zh) * 2020-04-20 2022-12-02 格兰尼斯制药公司 包含羟氯喹和/或氯喹的口服递送系统
CN114796126A (zh) * 2022-04-02 2022-07-29 复旦大学附属中山医院青浦分院(上海市青浦区中心医院) 关节腔注射用硫酸羟氯喹缓释微球及其制备方法
CN114796126B (zh) * 2022-04-02 2023-04-18 复旦大学附属中山医院青浦分院(上海市青浦区中心医院) 关节腔注射用硫酸羟氯喹缓释微球及其制备方法

Also Published As

Publication number Publication date
IN2012MN02896A (enExample) 2015-06-12
MX2013000242A (es) 2014-04-14
WO2011161644A1 (en) 2011-12-29
CA2803093A1 (en) 2011-12-29
US20130202556A1 (en) 2013-08-08
AU2011268498A1 (en) 2013-01-31
US8575195B2 (en) 2013-11-05
EP2585065A1 (en) 2013-05-01
BR112012033022A2 (pt) 2016-12-20
US8987302B2 (en) 2015-03-24
US20130121965A1 (en) 2013-05-16
JP2013529627A (ja) 2013-07-22

Similar Documents

Publication Publication Date Title
CN103096891A (zh) 利用羟氯喹或羟氯喹和抗病毒剂的组合治疗丙型肝炎病毒相关疾病
Pawlotsky New antiviral agents for hepatitis C
CN105148275A (zh) 丙型肝炎病毒抑制剂的组合
CN104023726A (zh) 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
MX2011002602A (es) Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina.
WO2009046369A2 (en) Use of a specific dosage regimen of ifn-alpha and ribavirin for treating hepatitis c
WO2008024843A2 (en) Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein
EP2776024A1 (en) Methods and compositions for treating hepatitis c virus
JP2012503669A (ja) 肝炎を治療するためのｐｅｇ−インターフェロン、リバビリンおよびｖｘ−９５０を含む治療レジメ
US8912141B2 (en) Treatment of hepatitis C virus
WO2013024158A1 (en) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
JP2013542206A (ja) Ｃ型肝炎ウイルス感染症の新規治療
JP6110791B2 (ja) Ｃ型肝炎ウイルス感染症の新規治療
CN1561227A (zh) 在治疗失败的病人中治疗丙型肝炎病毒感染的方法
TWI798578B (zh) 棘白菌素類化合物於治療黃病毒感染症的用途
JP2014509628A (ja) Ｃ型肝炎ウイルス感染症を治療するためのアリスポリビル
Abdel-Moneim et al. Medication of chronic hepatitis C: a review on sofosbuvir as a new antiviral drug
Gelderblom et al. [592] NEOPTERIN AND ALT AS MARKERS OF INFLAMMATION IN CHRONIC HEPATITIS C PATIENTS DURING ADMINISTRATION OF THE HCV NS3-4A PROTEASE INHIBITOR TELAPREVIR (VX-950) IN COMBINATION WITH PEGINTERFERON ALFA 2a
US20150328280A1 (en) Alisporivr for treatment of hepatitis c virus infection
WO2015136455A1 (en) New treatments of hepatitis c virus infection
CN111163779A (zh) 治疗HcV的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130508